Alkermes Plc Stock Price, News & Analysis

Alkermes (Nasdaq: ALKS) agreed to increase its recommended offer to acquire Avadel (Nasdaq: AVDL) to up to $22.50 per share — consisting of $21.00 cash plus one non-transferable contingent value right (CVR) payable up to $1.50 if final FDA approval for LUMRYZ for idiopathic hypersomnia in adults is achieved by the end of 2028.

The Increased Offer values Avadel at up to approximately $2.37 billion. The Amended Agreement was approved by both boards and the transaction remains expected to close in Q1 2026, subject to customary conditions and an extended End Date. J.P. Morgan provided fully committed financing for Alkermes.

Alkermes (Nasdaq: ALKS) responded on November 14, 2025 to Avadel's announcement about a possible Lundbeck offer for Avadel. Alkermes said its board is considering options with advisors and reiterated contractual protections in the existing Transaction Agreement.

Key contractual points: Avadel cannot terminate the agreement to accept a Company Superior Proposal unless its board, in good faith, determines doing so meets fiduciary duties and Avadel gives Alkermes at least five (5) Business Days written notice and engages in good‑faith discussions about amendments. Avadel also cannot change its board recommendation or sign with Lundbeck until those steps occur. Alkermes said a further announcement will follow as appropriate and will post this release on its website by 12:00 p.m. ET on November 17, 2025.

Alkermes (Nasdaq: ALKS) announced positive topline results from the Vibrance-2 phase 2 study of once-daily alixorexton in patients with narcolepsy type 2 on Nov. 12, 2025. In a randomized, double-blind trial (n=93) alixorexton met dual primary endpoints at week eight: clinically meaningful improvements in wakefulness (MWT) and excessive daytime sleepiness (ESS) versus placebo.

By pre-specified analysis, the 14 mg and 18 mg doses achieved statistical significance on MWT, and the 18 mg dose achieved statistical significance on ESS. Alixorexton was generally well tolerated; most TEAEs were mild-to-moderate and no serious TEAEs were reported. Alkermes plans to start a global phase 3 program in Q1 2026.

Alkermes (Nasdaq: ALKS) said management will participate in two investor conferences in November 2025: the Stifel 2025 Healthcare Conference on Nov. 13, 2025 at 2:40 p.m. ET and the Jefferies Global Healthcare Conference in London on Nov. 19, 2025 at 11:30 a.m. ET.

Both events will be webcast live and the webcasts will be available under the Investors tab at www.alkermes.com and archived for 14 days.

Alkermes (Nasdaq: ALKS) filed an Opening Position Disclosure (Form 8.1(a)&(b)) under Irish Takeover Panel rules on 5 November 2025 with a position date of 3 November 2025. The form names Avadel Pharmaceuticals plc as the related offeror/offeree and states Alkermes as the offeror. The disclosure reports no indemnities, option arrangements, or derivative agreements and no supplemental Form 8 attached. It lists J.P. Morgan staff holdings totalling 13,553 ordinary shares (0.0139%) in Avadel, split between two entities (53 and 13,500 shares).

Alkermes (Nasdaq: ALKS) reported Q3 2025 total revenues of $394.2 million and GAAP net income of $82.8 million (diluted EPS $0.49) for the quarter ended Sept. 30, 2025. Total proprietary net sales were $317.4 million, led by VIVITROL $121.1M, ARISTADA i $98.1M and LYBALVI $98.2M (LYBALVI +32% revenue, +25% prescriptions vs Q3 2024).

The company recorded cash and investments of $1.14 billion and raised its 2025 outlook: total revenues to $1.43–$1.49B, GAAP net income to $230–$250M, EBITDA to $270–$290M and adjusted EBITDA to $365–$385M. R&D expense for the quarter was $81.7M.

Alkermes (Nasdaq: ALKS) agreed to acquire Avadel (Nasdaq: AVDL) for $18.50 per share in cash plus a non-transferable CVR of $1.50 per share contingent on FDA approval for idiopathic hypersomnia, valuing the deal at up to $20.00 per share and ≈$2.1 billion. The boards approved the transaction, which is expected to close in Q1 2026 subject to regulatory and shareholder approvals.

The acquisition adds FDA-approved LUMRYZ (once-at-bedtime sodium oxybate) with expected 2025 net revenues of $265–$275 million, ~3,100 patients on therapy as of June 30, 2025, and a U.S. oxybate-eligible population >50,000. Alkermes expects the deal to be immediately accretive and will finance with cash on hand plus new debt, with J.P. Morgan providing committed financing.

Alkermes (Nasdaq: ALKS) will report third quarter 2025 financial results and host a conference call and webcast on Oct 28, 2025 at 8:00 a.m. ET (12:00 p.m. GMT). The event will include slides available on the company's Investors website and a replay posted about two hours after the event.

Live access: U.S. dial +1 877 407 2988; international dial +1 201 389 0923. Alkermes is a global biopharmaceutical company focused on neuroscience with marketed products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline including narcolepsy and idiopathic hypersomnia. Headquarters in Ireland with R&D in Massachusetts and manufacturing in Ohio.

Alkermes (Nasdaq: ALKS) has appointed Joshua Reed as Chief Financial Officer, effective September 15, 2025. Reed brings over 30 years of financial leadership experience in biotechnology and pharmaceutical sectors, most recently serving as CFO of Omega Therapeutics.

Reed's extensive background includes CFO roles at Aldeyra Therapeutics and leadership positions at Bristol Myers Squibb, where he served as Vice President and Head of Finance Operations for the U.S. and Puerto Rico. He currently serves on the board of Scholar Rock Holding Corporation and holds degrees from Rutgers University and the University of Michigan's Ross School of Business.